Gary Nachman
Stock Analyst at Raymond James
(3.46)
# 947
Out of 4,761 analysts
101
Total ratings
59.42%
Success rate
1.47%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Reiterates: Outperform | $218 → $220 | $202.08 | +8.87% | 14 | Feb 3, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $22.64 | +23.67% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $250.59 | +18.92% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $23.49 | +57.51% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $3.17 | +530.91% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $25.16 | +47.06% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $15.75 | +20.63% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $303.01 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $37.70 | -20.42% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $3.01 | +132.56% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $3 | $0.57 | +423.83% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $136.01 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $7.83 | -48.91% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $5.67 | +429.10% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $32.32 | +107.30% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.03 | +956.11% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $11.25 | +24.44% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $75 | $5.77 | +1,199.83% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $7.31 | +447.20% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $16.74 | -40.26% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $20.09 | +49.33% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $2.99 | +24,983.61% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $7.31 | +9.44% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $31.28 | -32.86% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $3.25 | +330.77% | 2 | Jun 14, 2018 |
AbbVie
Feb 3, 2025
Reiterates: Outperform
Price Target: $218 → $220
Current: $202.08
Upside: +8.87%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $22.64
Upside: +23.67%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $250.59
Upside: +18.92%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $23.49
Upside: +57.51%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $3.17
Upside: +530.91%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $25.16
Upside: +47.06%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $15.75
Upside: +20.63%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $303.01
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $37.70
Upside: -20.42%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $3.01
Upside: +132.56%
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.57
Upside: +423.83%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $136.01
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $7.83
Upside: -48.91%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $5.67
Upside: +429.10%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $32.32
Upside: +107.30%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.03
Upside: +956.11%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $11.25
Upside: +24.44%
Nov 14, 2022
Maintains: Outperform
Price Target: $90 → $75
Current: $5.77
Upside: +1,199.83%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $7.31
Upside: +447.20%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $16.74
Upside: -40.26%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $20.09
Upside: +49.33%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $2.99
Upside: +24,983.61%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $7.31
Upside: +9.44%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $31.28
Upside: -32.86%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $3.25
Upside: +330.77%